Analysis reveals that biased clinical testing affects Paxlovid's effectiveness in COVID-19, suggesting flaws in medical evaluation processes.
Despite incredibly underwhelming evidence from the outset, a massive amount of money was spent (or wasted) on Paxlovid during the COVID pandemic. Some of the issues are endemic to medical science. When we allow companies to test their own products with billions of dollars on the line, the results are horrendously biased from the outset. […]
No takes yet. Share an insight, caveat, or question.
Justin Morgenstern (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: